Wegovy (semaglutide) is a once-a-week injection thats approved by the Food and Drug Administration (FDA) to: Reduce excess body weight and maintain weight reduction in: Adults with a body mass index (BMI) of 30 or higher Adults with a BMI of 27 or higher who also have weight-related medical problems, such as high cholesterol or high blood pressure Adolescents ages 1217 who are at or above the 95th percentile on sex- and age-specific growth charts Reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and a BMI of 27 or higher Wegovy belongs to a family of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists)
Fortino, the leading Semaglutide Doctor in NJ & PA
Gursoy A, Erdogan MF, Cin MO, Cesur M, Baskal N
Benefits of starting with lower medication levels extend beyond physical tolerance to include psychological advantages that support long-term success
In clinical studies, patients using semaglutide for weight loss have seen an average weight reduction of around 10-15% of their body weight over the course of several months
Its value depends on how confident you are in staying the course
